Weifeng Liu

11PUBLICATIONS
16CO-AUTHORS
Predictive and prognostic markersRadiation therapyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Solid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 27, 2026
Prognostic and Predictive Value of CD163+ Macrophages for Neoadjuvant Chemotherapy in Osteosarcoma.

|Feb 13, 2026
A Dangerous Region Generation Method for Computer-Assisted Pelvic Bone Tumor Resection Surgery: A Retrospective Study.

Daming Pang, Zhuoyu Li, Yang Sun

|Nov 26, 2025
JMT103 versus Non-Denosumab or Denosumab Treatment in Chinese Patients with Unresectable or Surgically Challenging Giant Cell Tumor of Bone: A Propensity Score-Matched Comparison.

Hairong Xu, Yong Zhou, Feng Wei

|Nov 05, 2024
Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II study.

Hairong Xu, Yong Zhou, Li Liang

|Sep 20, 2023
The correlation between clinical outcomes and genomic analysis with high risk factors for the progression of osteosarcoma.

Weifeng Liu, Huanqing Cheng, Zhen Huang

|Sep 04, 2023
Carboxypeptidase E is a prognostic biomarker co-expressed with osteoblastic genes in osteosarcoma.

Dafu Chen, Ben Wan, Yuning Cheng

Pageof 2

Frequent Collaborators

3 joint publications

Xiaohui Niu

2 joint publications

Dafu Chen

1 joint publications

Ben Wan

1 joint publications

Renxian Wang